Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P18507: Variant p.Arg323Gln

Gamma-aminobutyric acid receptor subunit gamma-2
Gene: GABRG2
Feedback?
Variant information Variant position: help 323 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 323 (R323Q, p.Arg323Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GEFSP3 and DEE74; does not affect protein abundance; decreases cell surface expression; decreases current amplitude in response to GABA; increases zinc sensitivity; accelerates deactivation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 323 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 475 The length of the canonical sequence.
Location on the sequence: help ARTSLGITTVLTMTTLSTIA R KSLPKVSYVTAMDLFVSVCF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCF

Mouse                         ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCF

Rat                           ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCF

Bovine                        ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCF

Chicken                       ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCF
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 40 – 475 Gamma-aminobutyric acid receptor subunit gamma-2
Topological domain 323 – 334 Extracellular
Helix 301 – 323



Literature citations
De novo GABRG2 mutations associated with epileptic encephalopathies.
Shen D.; Hernandez C.C.; Shen W.; Hu N.; Poduri A.; Shiedley B.; Rotenberg A.; Datta A.N.; Leiz S.; Patzer S.; Boor R.; Ramsey K.; Goldberg E.; Helbig I.; Ortiz-Gonzalez X.R.; Lemke J.R.; Marsh E.D.; Macdonald R.L.;
Brain 140:49-67(2017)
Cited for: VARIANTS DEE74 THR-106; THR-107; SER-282; GLN-323; TRP-323 AND LEU-343; CHARACTERIZATION OF VARIANTS DEE74 THR-106; THR-107; SER-282; GLN-323; TRP-323 AND LEU-343; SUBCELLULAR LOCATION; FUNCTION; TRANSPORTER ACTIVITY; ACTIVITY REGULATION; Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.
Carvill G.L.; Heavin S.B.; Yendle S.C.; McMahon J.M.; O'Roak B.J.; Cook J.; Khan A.; Dorschner M.O.; Weaver M.; Calvert S.; Malone S.; Wallace G.; Stanley T.; Bye A.M.; Bleasel A.; Howell K.B.; Kivity S.; Mackay M.T.; Rodriguez-Casero V.; Webster R.; Korczyn A.; Afawi Z.; Zelnick N.; Lerman-Sagie T.; Lev D.; Moeller R.S.; Gill D.; Andrade D.M.; Freeman J.L.; Sadleir L.G.; Shendure J.; Berkovic S.F.; Scheffer I.E.; Mefford H.C.;
Nat. Genet. 45:825-830(2013)
Cited for: VARIANT GEFSP3 GLN-323;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.